| Literature DB >> 35542222 |
Zhiguo Liu1, Xilong Zheng2, Yanan Wang3, Mengyue Tang1, Shilin Chen1, Fangbo Zhang1, Li Li3, Cun Zhang1, Yi Sun1.
Abstract
Twelve new compounds including four isoflavonolignans (1a/1b and 2a/2b), two neolignans (3a/3b), and six isoflavonoids (5-10), together with seven known compounds (4 and 11-16) were isolated from the stems of Pisonia umbellifera. The structures were elucidated on the basis of comprehensive spectroscopic analyses and ECD calculation methods. Compounds 1-3 were present as enantiomers that were successfully separated by chiral HPLC. Compounds 1a/1b and 2a/2b are the first examples of isoflavonolignans with a pyranoid ring linking up the isoflavonoid and the monolignol from nature. A putative biosynthetic pathway for the isoflavonolignans was deduced. The anti-inflammatory and cytotoxic activities for all compounds were evaluated. This journal is © The Royal Society of Chemistry.Entities:
Year: 2018 PMID: 35542222 PMCID: PMC9080244 DOI: 10.1039/c8ra02240b
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
Fig. 1Structures of compounds 1–16.
1H (600 MHz) and 13C NMR (150 MHz) NMR data for compounds 1–3
| Position | 1 | 2 | 3 | |||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
| 1 | 132.3 | |||||
| 2 | 8.09, s | 156.0 | 8.19, s | 157.2 | 6.98, br s | 112.2 |
| 3 | 122.9 | 122.0 | 145.6 | |||
| 4 | 182.5 | 182.8 | 149.4 | |||
| 4 | 104.8 | 106.0 | ||||
| 5 | 157.2 | 158.1 | 130.4 | |||
| 6 | 106.5 | 107.0 | 6.98, br s | 116.6 | ||
| 7 | 159.7 | 160.1 | 5.59, d (16.2) | 134.3 | ||
| 8 | 103.2 | 103.8 | 6.19, m | 124.3 | ||
| 8 | 153.3 | 154.7 | ||||
| 9 | 2.74, dd (17.4, 10.2) | 21.8 | 2.73, dd (16.8, 10.8) | 22.6 | 4.08, dd (6.0, 1.2) | 74.3 |
| 2.98, dd (17.4, 5.4) | 2.99, dd (16.8, 4.8) | |||||
| 8-CH3 | 2.22, s | 7.7 | 2.23, s | 7.6 | ||
| 3-OCH3 | 3.90, s | 56.8 | ||||
| 9-OCH3 | 3.39, s | 58.0 | ||||
| 1′ | 120.4 | 119.8 | 134.3 | |||
| 2′ | 156.2 | 156.8 | 6.96, d (1.8) | 110.6 | ||
| 3′ | 7.10, dd (7.8, 1.2) | 119.8 | 6.94, dd (7.8, 1.2) | 117.2 | 149.1 | |
| 4′ | 7.36, ddd (7.8, 7.8, 1.8) | 130.8 | 7.29, ddd (7.8, 7.8, 1.8) | 132.7 | 147.7 | |
| 5′ | 7.00, ddd (7.8, 7.8, 1.2) | 121.3 | 6.92, ddd (7.8, 7.8, 1.2) | 120.7 | 6.79, d (7.8) | 116.2 |
| 6′ | 7.19, dd (7.8, 1.8) | 129.9 | 7.26, dd (7.8, 1.8) | 130.9 | 6.84, dd (7.8, 1.8) | 119.9 |
| 7′ | 5.50, d (6.6) | 89.7 | ||||
| 8′ | 3.63, m | 52.7 | ||||
| 9′ | 3.65, m | 75.7 | ||||
| 3.72, m | ||||||
| 3′-OCH3 | 3.84, s | 56.4 | ||||
| 9′-OCH3 | 3.41, s | 59.3 | ||||
| 1′′ | 131.1 | 131.4 | ||||
| 2′′ | 6.92, d (1.8) | 109.1 | 6.73, s | 105.3 | ||
| 3′′ | 147.0 | 149.4 | ||||
| 4′′ | 146.1 | 136.7 | ||||
| 5′′ | 6.95, d (7.8) | 114.6 | 149.4 | |||
| 6′′ | 6.91, dd (7.8, 1.8) | 120.0 | 6.73, s | 105.3 | ||
| 7′′ | 5.02, d (9.0) | 81.0 | 5.02, d (8.4) | 82.0 | ||
| 8′′ | 2.25, m | 39.7 | 2.26, m | 40.8 | ||
| 9′′ | 3.55, dd (10.8, 4.8) | 63.4 | 3.43, dd (10.8, 4.8) | 63.4 | ||
| 3.65, dd (10.8, 4.8) | 3.55, dd (10.8, 4.8) | |||||
| 3′′-OCH3 | 3.92, s | 56.2 | 3.87, s | 56.8 | ||
| 5′′-OCH3 | 3.87, s | 56.8 | ||||
| 5-OH | 12.54, s | |||||
Recorded in CDCl3.
Recorded in methanol-d4.
Fig. 2The key HMBC (H→C) and COSY (—) (a), and NOESY (b) correlations of 1.
Fig. 3(A) Chiral-phase HPLC analytical chromatogram of 1. (B) Comparison of calculated and experimental ECD spectra of 1.
Fig. 4The key HMBC (H→C) and COSY (—) (a), and NOESY (b) correlations of 2.
Fig. 5(A) Chiral-phase HPLC analytical chromatogram of 2. (B) Comparison of calculated and experimental ECD spectra of 2.
Fig. 6The key HMBC (H→C) and COSY (—) (a), and NOESY (b) correlations of 3.
Fig. 7(A) Chiral-phase HPLC analytical chromatogram of 3. (B) Comparison of calculated and experimental ECD spectra of 3.
1H (600 MHz, CDCl3) and 13C (150 MHz, CDCl3) NMR data for compounds 5–7
| Position | 5 | 6 | 7 | |||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
| 2 | 8.09, s | 156.0 | 8.08, s | 155.9 | 8.12, s | 154.8 |
| 3 | 123.1 | 123.0 | 125.2 | |||
| 4 | 182.5 | 182.4 | 181.3 | |||
| 4 | 104.6 | 104.5 | 104.5 | |||
| 5 | 156.5 | 156.3 | 165.4 | |||
| 6 | 105.6 | 105.9 | 109.9 | |||
| 7 | 162.4 | 162.5 | 168.2 | |||
| 8 | 103.5 | 103.4 | 102.5 | |||
| 8 | 154.9 | 154.8 | 158.2 | |||
| 9 | 4.90, s | 67.8 | 4.92, s | 65.9 | ||
| 6-CH3 | 2.16, s | 6.7 | ||||
| 8-CHO | 10.37, s | 189.8 | ||||
| 8-CH3 | 2.25, s | 7.4 | 2.24, s | 7.3 | ||
| 9-OCH3 | 3.53, s | 58.9 | ||||
| 9-OCH2CH3 | 3.70, dd (14.4, 7.2) | 67.2 | ||||
| 9-OCH2CH3 | 1.33, t (7.2) | 15.1 | ||||
| 1′ | 120.2 | 120.2 | 119.0 | |||
| 2′ | 156.2 | 156.1 | 155.9 | |||
| 3′ | 7.10, dd (7.8, 1.2) | 119.8 | 7.10, dd (7.8, 1.2) | 119.8 | 7.11, dd (7.8, 1.2) | 119.9 |
| 4′ | 7.36, ddd (7.8, 7.8, 1.8) | 130.8 | 7.36, ddd (7.8, 7.8, 1.8) | 130.8 | 7.40, ddd (7.8, 7.8, 1.8) | 131.4 |
| 5′ | 7.00, ddd (7.8, 7.8, 1.2) | 121.3 | 7.00, ddd (7.8, 7.8, 1.2) | 121.3 | 7.04, ddd (7.8, 7.8, 1.2) | 121.6 |
| 6′ | 7.18, dd (7.8, 1.8) | 129.9 | 7.17, dd (7.8, 1.8) | 129.9 | 7.19, dd (7.8, 1.8) | 130.2 |
| 5-OH | 12.59, s | 12.58, s | ||||
| 7-OH | 9.33, br s | 9.62, br s | ||||
| 2′-OH | 8.22, br s | 8.25, br s | ||||
1H (600 MHz, CDCl3) and 13C (150 MHz, CDCl3) NMR data for compounds 8–10
| Position | 8 | 9 | 10 | |||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
| 2 | 8.09, s | 156.2 | 8.15, s | 156.2 | 8.17, s | 156.6 |
| 3 | 123.6 | 123.7 | 123.6 | |||
| 4 | 182.7 | 182.8 | 183.0 | |||
| 4 | 104.0 | 107.6 | 107.9 | |||
| 5 | 166.0 | 160.2 | 158.4 | |||
| 6 | 106.7 | 115.6 | 118.3 | |||
| 7 | 166.2 | 164.6 | 163.7 | |||
| 8 | 103.7 | 112.5 | 110.0 | |||
| 8 | 159.2 | 153.5 | 154.9 | |||
| 6-CHO | 10.42, s | 193.0 | ||||
| 6-CH2OH | 4.84, s | 62.6 | ||||
| 6-CH3 | 2.26, s | 8.7 | ||||
| 7-OCH3 | 3.95, s | 54.2 | 3.92, s | 55.0 | ||
| 8-CH2OH | 4.93, s | 62.5 | ||||
| 8-CH3 | 2.23, s | 6.7 | 2.34, s | 8.5 | ||
| 1′ | 119.2 | 119.8 | 119.7 | |||
| 2′ | 155.9 | 156.1 | 155.9 | |||
| 3′ | 7.11, dd (7.8, 1.2) | 119.8 | 7.11, dd (7.8, 1.2) | 119.8 | 7.11, dd (7.8, 1.2) | 119.8 |
| 4′ | 7.39, ddd (7.8, 7.8, 1.8) | 131.3 | 7.38, ddd (7.8, 7.8, 1.8) | 131.0 | 7.38, ddd (7.8, 7.8, 1.8) | 131.0 |
| 5′ | 7.03, ddd (7.8, 7.8, 1.2) | 121.6 | 7.02, ddd (7.8, 7.8, 1.2) | 121.5 | 7.02, ddd (7.8, 7.8, 1.2) | 121.5 |
| 6′ | 7.19, dd (7.8, 1.8) | 130.0 | 7.17, dd (7.8, 1.8) | 130.1 | 7.18, dd (7.8, 1.8) | 130.0 |
| 5-OH | 12.62, s | 12.58, s | ||||
Fig. 8Possible biosynthetic pathway of compounds 1a/1b and 2a/2b from P. umbellifera.
Inhibitory effect of compounds 1–16 on LPS-induced NO production in macrophagesa
| Compounds | IC50 ± SD | Compounds | IC50 ± SD (μM) |
|---|---|---|---|
| 1a | >100 | 8 | >100 |
| 1b | >100 | 9 | >100 |
| 2a | >100 | 10 | >100 |
| 2b | >100 | 11 | 53.91 ± 0.45 |
| 3a | >100 | 12 | 84.32 ± 0.72 |
| 3b | >100 | 13 | 33.15 ± 1.18 |
| 4 | 73.90 ± 0.24 | 14 | >100 |
| 5 | 73.13 ± 0.66 | 15 | 11.30 ± 0.87 |
| 6 | >100 | 16 | 52.09 ± 1.21 |
| 7 | >100 | Resveratrol | 40.20 ± 0.94 |
Resveratrol was used as positive control. Results are presented as the means ± SD (n = 3).
Concentration necessary for 50% inhibition (IC50).
Cytotoxicity of compounds 1–16 (IC50 in μM)a on A549 and K562 cells
| Compounds | A549 | K562 | Compounds | A549 | K562 |
|---|---|---|---|---|---|
| 1a | – | – | 10 | – | – |
| 2a | – | – | 11 | 36.8 | 18.4 |
| 3a | – | – | 12 | 35.0 | 17.5 |
| 4 | 33.6 | 16.8 | 13 | – | 17.6 |
| 5 | 13.6 | 6.7 | 14 | – | 16.7 |
| 6 | 13.1 | 14.6 | 15 | 34.2 | 7.5 |
| 7 | – | 35.3 | 16 | – | 11.2 |
| 8 | – | – | Adriamycin | 2.9 | 2.0 |
| 9 | – | – |
Presents a pair of enantiomers; “–” presents IC50 values > 50 μM.